Literature DB >> 29222311

Role of the microenvironment across histological subtypes of NHL.

Karin Tarte1,2.   

Abstract

Recent progress in next-generation sequencing strategies has revealed the genetic landscape of B-cell non-Hodgkin lymphoma, but the tumor microenvironment is increasingly recognized as crucial to sustaining malignant B-cell survival and growth, subclonal evolution, and drug resistance. The tumor niche is made up of a dynamic and organized network of strongly heterogeneous immune and stromal cell subsets characterized by specific phenotypic, transcriptomic, and functional features. Nonmalignant cell recruitment and plasticity are dictated by lymphoma B cells, which convert their surrounding microenvironment into a supportive niche. In addition, they are also influenced by the crosstalk between the various components of this niche. In agreement with this, the B-cell lymphoma subtype is a key determinant of the organization of the tumor niche, but genetic alteration patterns, tumor localization, stage of the disease, and treatment strategy may also modulate its composition and activity. Moreover, the complex set of bidirectional interactions between B cells and their microenvironment has been proposed as a promising therapeutic target with the aim of reinforcing antitumor immunity and/or of abbrogating the lymphoma-promoting signals delivered by the tumor niche.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29222311      PMCID: PMC6142566          DOI: 10.1182/asheducation-2017.1.610

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  60 in total

1.  DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

Authors:  Rada Amin; Frédéric Mourcin; Fabrice Uhel; Céline Pangault; Philippe Ruminy; Loic Dupré; Marion Guirriec; Tony Marchand; Thierry Fest; Thierry Lamy; Karin Tarte
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

2.  Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation.

Authors:  Chris G Mueller; Charlotte Boix; Wing-Hong Kwan; Cécile Daussy; Emilie Fournier; Wolf H Fridman; Thierry J Molina
Journal:  J Leukoc Biol       Date:  2007-06-15       Impact factor: 4.962

3.  Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemura; Naoe Goto; Senji Kasahara; Masahito Shimizu; Hiroyasu Ito; Kuniaki Saito; Yoshinobu Hirose; Tetsuya Yamada; Takeshi Takahashi; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Ann Hematol       Date:  2010-10-12       Impact factor: 3.673

Review 4.  B-cell receptor signaling in diffuse large B-cell lymphoma.

Authors:  Ryan M Young; Arthur L Shaffer; James D Phelan; Louis M Staudt
Journal:  Semin Hematol       Date:  2015-01-15       Impact factor: 3.851

5.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

6.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

8.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

9.  PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.

Authors:  Z-Z Yang; D M Grote; S C Ziesmer; B Xiu; A J Novak; S M Ansell
Journal:  Blood Cancer J       Date:  2015-02-20       Impact factor: 11.037

10.  IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.

Authors:  B Xiu; Y Lin; D M Grote; S C Ziesmer; M P Gustafson; M L Maas; Z Zhang; A B Dietz; L F Porrata; A J Novak; A-B Liang; Z-Z Yang; S M Ansell
Journal:  Blood Cancer J       Date:  2015-07-31       Impact factor: 11.037

View more
  9 in total

1.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Blood Adv       Date:  2020-11-24

Review 2.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

3.  Editorial: B Cell Non-Hodgkin's Lymphoma & Tumor Microenvironment Crosstalk: An Epigenetic Matter?

Authors:  Y Denizot; M S Braza; R Amin
Journal:  Front Genet       Date:  2022-05-19       Impact factor: 4.772

4.  Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.

Authors:  Cédric Ménard; Delphine Rossille; Joelle Dulong; Tien-Tuan Nguyen; Ilenia Papa; Maelle Latour; Nadège Bescher; Isabelle Bezier; Myriam Chouteau; Thierry Fest; Roch Houot; Franck Morschhauser; Karin Tarte
Journal:  Blood Adv       Date:  2021-04-27

Review 5.  Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.

Authors:  Hélène Augé; Anne-Béatrice Notarantonio; Romain Morizot; Anne Quinquenel; Luc-Matthieu Fornecker; Sébastien Hergalant; Pierre Feugier; Julien Broséus
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

6.  The biology of the tumor microenvironment in DLBCL: Targeting the "don't eat me" signal.

Authors:  Daisuke Ennishi
Journal:  J Clin Exp Hematop       Date:  2021-09-10

Review 7.  Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.

Authors:  Arushi Khurana; Yi Lin
Journal:  Curr Treat Options Oncol       Date:  2022-02-25

Review 8.  Immunotherapy in the treatment of lymphoma.

Authors:  Lazar S Popovic; Gorana Matovina-Brko; Maja Popovic; Milica Popovic; Ana Cvetanovic; Ivan Nikolic; Biljana Kukic; Dragana Petrovic
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

Review 9.  Microenvironment Cell Contribution to Lymphoma Immunity.

Authors:  Deepika Kumar; Mina L Xu
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.